CagriSema Weight Loss: Trial Results, Comparisons, and What to Expect

Novo Nordisk already dominates the GLP-1 market with semaglutide (Ozempic, Wegovy). But Eli Lilly's tirzepatide, which combines GLP-1 and GIP activity, produces more weight loss than semaglutide alone. Novo Nordisk needed a response. Their answer was CagriSema: combine semaglutide with cagrilintide, a long-acting amylin analogue. Amylin is a hormone co-secreted with insulin by the pancreas. It promotes satiety, slows gastric emptying, and reduces glucagon secretion. By adding amylin activity to semaglutide's GLP-1 activity, Novo Nordisk aimed to create a combination that could match or beat tirzepatide.

CagriSema is a once-weekly subcutaneous injection containing two active ingredients:

• Semaglutide (2.4 mg). A GLP-1 receptor agonist that reduces appetite, slows digestion, and improves insulin secretion. This is the same molecule in Wegovy.
• Cagrilintide (2.4 mg). A long-acting amylin analogue that activates amylin receptors. Amylin promotes fullness, reduces food intake, and lowers glucagon levels.

The two drugs hit complementary pathways. GLP-1 acts primarily through brain appetite centers. Amylin acts through gut-brain signaling and stomach emptying. Together, they produce more satiety than either alone.

REDEFINE 1 (people without diabetes):

• 20.4% average weight loss at 68 weeks
• 22.7% with full treatment adherence
• Compared to 11.5% with cagrilintide alone, 14.9% with semaglutide alone, 3% with placebo

REDEFINE 2 (people with type 2 diabetes):

• 13.7% average weight loss
• 15.7% with full adherence
• Significantly better than semaglutide alone in this population

REDEFINE 4 (head-to-head vs tirzepatide):

• CagriSema did NOT outperform tirzepatide
• After 84 weeks, tirzepatide produced comparable or slightly better weight loss
• This was a setback for Novo Nordisk's competitive positioning

Cardiovascular data:

• REDEFINE 1 also showed CagriSema reduced predicted atherosclerotic cardiovascular disease risk
• This is meaningful for people with obesity who have heart disease risk factors

People in CagriSema trials report side effects similar to semaglutide: nausea, diarrhea, constipation, and reduced appetite. The nausea tends to be more intense during dose escalation than with semaglutide alone, likely because you're hitting two appetite pathways simultaneously. One user on r/Peptides who follows the trial data closely noted that “the REDEFINE 4 results were a gut punch for people hoping CagriSema would be the next big thing. It's good, but it's not clearly better than tirzepatide, and tirzepatide is already available.“

• Significant weight loss, in the 15-23% range depending on adherence and diabetes status
• Strong appetite suppression from two complementary mechanisms
• Improved blood sugar control
• Reduced cardiovascular disease risk markers
• Better satiety signals compared to semaglutide alone

| Metric | CagriSema | Tirzepatide | |--------|-----------|-------------| | Average weight loss | 20-23% | 20-23% | | Mechanism | GLP-1 + amylin | GLP-1 + GIP | | Dosing | Weekly injection | Weekly injection | | FDA status | Not yet approved | Approved | | Head-to-head | Did not beat tirzepatide | Won or tied | The bottom line: CagriSema and tirzepatide produce similar weight loss. Tirzepatide is available now. CagriSema is not. For someone starting treatment today, tirzepatide is the more practical choice.

Like retatrutide, CagriSema is a pharmaceutical, not a research peptide. But people interested in the amylin pathway sometimes explore:

• Pramlintide (Symlin) is an existing amylin analogue approved for diabetes
• BPC-157 for GI support during GLP-1 treatment
• MOTs-C for metabolic health beyond weight loss